MacDougall Biomedical Communications is guiding media and investor relations for Rib-X Pharmaceuticals, the antibiotic maker planning an initial public offering worth up to $80M.
New Haven-based Rib-X is focused on developing antibiotics for hospital treatment of serious and life-threatening infections like bacterial skin infections. Its IPO prospectus filed Nov. 28 notes the hospital antibiotic market hit $10B in 2006 and in the seven major global drug markets totaled $20B in 2009.
MacDougall, based in Wellesley, Mass., has worked the Rib-X account since 2010.
The venture-backed drug maker, founded in 2001, includes 2009 Nobel Prize for chemistry winner Thomas Steitz, a professor at Yale University. He chairs the company’s scientific advisory board.